Zacks Investment Research
13 Jul 2026, 22:51 UTC · 1h ago
Is Johnson & Johnson Stock Poised for New Highs as Q2 Results Approach?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
13 Jul 2026, 22:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Johnson & Johnson is scheduled to report Q2 earnings on Wednesday, July 15, with consensus estimates of $2.85 EPS and $25.18 billion in revenue. — Earnings releases for mega-cap healthcare stocks typically drive short-term price volatility based on beats or misses relative to expectations.
+0.30JNJ shares have increased by more than 20% year-to-date, recently hitting all-time highs of $269. — Strong technical momentum and new highs often attract further trend-following buyers but can also signal a potential overbought condition.
+0.20The company's valuation is currently 22X forward earnings, which is slightly below the S&P 500 benchmark. — A relative valuation discount compared to the broader market may attract value-oriented investors, though it is less volatile than earnings data.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The article describes the company as a strong performer with a premier dividend and attractive valuation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
